Wearable sensors and adaptive algorithms can reveal changes between appointments. Trials in heart disease and diabetes show why the clinical response matters as much as the quantity of data collected.
A patient living with chronic disease spends most of their time outside the clinic. Home sensors can make some of that interval visible, recording changes that a scheduled appointment might miss. Artificial intelligence promises to identify patterns in those measurements and direct attention towards the people who need help.
The promise becomes meaningful only when the information changes a decision. A warning of worsening heart failure needs a clinical response. A possible irregular rhythm needs confirmation and an assessment of its implications. In diabetes, an automated system can connect a glucose measurement directly to insulin delivery, bringing the sensing and response stages much closer together.
These are different interventions, and their evidence should not be pooled under a single claim that remote monitoring works. Nor is every digital monitoring system an AI product. Conventional signal processing, machine learning and adaptive control have distinct roles. For European services planning care closer to home, the useful comparison is how each approach changes treatment, patient workload and clinical outcomes.
Predicting a heart failure admission is only the first step
The LINK-HF study tested a wearable sensor combined with personalised analytics in 100 patients following a heart failure admission. Published in 2020, it found that the system could identify physiological changes preceding readmission, with a median interval of 6.5 days between the initial alert and hospitalisation.
This was a prediction study, rather than a trial demonstrating that acting on the alerts prevented admissions. The interval suggested an opportunity to intervene, but it did not determine which response would be effective or whether every predicted event could be avoided.
That distinction is particularly important for procurement. A hospital admission is not simply an error that a better forecast will eliminate. Some patients need inpatient treatment despite early recognition, while others may benefit from an outpatient assessment or a change in management.
The next task is therefore to connect the prediction with a response that can be delivered reliably at home. Services need to specify who reviews the data, how quickly patients can be contacted and what happens when the measurements are incomplete. Those choices determine whether additional visibility becomes an effective extension of clinical care.
A 2026 trial tests the response to notifications
LINK-HF2 directly examined that next step. Results reported in a March 2026 American College of Cardiology conference abstract involved 171 analysed patients at five US Veterans Affairs medical centres. All received a wearable sensor after an acute heart failure admission; the intervention group had AI-generated notifications emailed to the clinical team, while control notifications were not emailed.
The intervention prompted documented responses, including increased monitoring and medication adjustments. However, heart failure hospitalisation was similar between groups: the hazard ratio was 0.97, with a wide 95% confidence interval of 0.46–2.01. The result does not establish benefit or equivalence. The study was small, and the available report is a conference abstract rather than a full trial publication.
Notifications of impending exacerbation were reduced in the intervention group, but this algorithm-related endpoint should not be substituted for the hospitalisation result. A change in the signal a system generates is different from a demonstrated change in events experienced by patients.
The finding gives researchers a useful direction: refine the action pathway and test it at sufficient scale. It also gives purchasers a reason to ask for clinical endpoints beyond successful alert delivery and staff engagement.
Finding an irregular rhythm creates another decision
Germany’s eBRAVE-AF trial tested a practical digital screening pathway using participants’ own smartphones. It randomised 5,551 insurance policyholders without known atrial fibrillation to digital screening or usual care. An app assessed pulse irregularity, with abnormal findings investigated using a 14-day external electrocardiogram recorder.
Within six months, the digital pathway more than doubled the odds of newly diagnosed atrial fibrillation that an independent physician treated with oral anticoagulation. The odds ratio was 2.12, with a 95% confidence interval of 1.19–3.76. The endpoint joined detection to a treatment decision, but did not establish fewer strokes.
This is evidence about an algorithm-assisted screening pathway, rather than proof that every consumer device or AI classifier offers the same benefit. The confirmatory recorder and subsequent physician decision were integral to the intervention.
For European services, the example illustrates a potential route from a widely available device into formal assessment. It also raises a capacity question: if digital screening identifies more people requiring confirmation, the service must be able to provide and interpret the follow-up test. Availability on a smartphone does not remove that clinical workload.
More diagnoses do not guarantee fewer strokes
The Danish LOOP trial provides an important comparison for interpreting detection gains. It randomised 6,004 people aged 70–90 with additional stroke risk factors to implantable loop recorder monitoring or usual care. Atrial fibrillation was diagnosed in 31.8% of the monitored group and 12.2% of controls.
Despite the increase in detection and anticoagulation, stroke or systemic arterial embolism occurred in 4.5% and 5.6%, respectively, a difference that was not statistically significant. The hazard ratio was 0.80, with a 95% confidence interval of 0.61–1.05.
LOOP was not a trial of a new AI model. Its relevance is the clinical boundary it demonstrates: improved surveillance and more treatment do not by themselves establish the intended patient benefit. Different populations, episode characteristics and treatment pathways can change the balance.
This also explains why monitoring programmes need a clear purpose before choosing a device. Detecting previously unrecognised disease, managing an established diagnosis and preventing a major event are related objectives, but they require different evaluation designs. A service should identify which one it is promising to achieve.
Diabetes closes the gap between sensing and treatment
Automated insulin delivery offers a contrasting model. Rather than sending every change to a distant clinical team, a control algorithm adjusts delivery using continuous glucose measurements. These systems should be described according to their actual control technology, rather than automatically labelled as machine learning.
A Cambridge-led 2023 study evaluated fully closed-loop delivery in adults with insulin-treated type 2 diabetes. In a randomised crossover design, 26 participants underwent two eight-week periods comparing the CamAPS HX system with standard insulin therapy. Time within the target glucose range was 66.3% during closed-loop use and 32.3% during control treatment. No severe hypoglycaemia occurred, although one treatment-related serious adverse event involved a pump cannula site abscess.
The trial demonstrated a substantial short-term improvement in glucose control in a small, selected population. It did not establish long-term complication rates or performance across all groups with type 2 diabetes.
A larger 2025 multicentre trial randomised 319 adults with insulin-treated type 2 diabetes to automated delivery or their previous delivery method, with both groups receiving continuous glucose monitoring. At 13 weeks, the adjusted difference in glycated haemoglobin change favoured automation by 0.6 percentage points. One severe hypoglycaemia event occurred in the automated delivery group.
The two studies tested different systems and should not be treated as interchangeable. Together, they show why a defined response to a sensor reading can generate more clinically informative evidence than monitoring alone.
Designing a service that people can use
A remote monitoring service extends clinical responsibilities into daily life. Its design needs to account for the work transferred to patients: maintaining devices, responding to messages and deciding when a technical problem needs attention. A system that reduces visits but creates confusing daily demands may deliver a different experience from the one its designers intended.
The relevant evaluation therefore extends beyond accuracy and hospital activity. It should examine sustained use, missed transmissions, contacts required to resolve problems and whether patients understand the response arrangements. Measures of staff time should include follow-up calls and assessment of false alarms, rather than counting only the minutes spent reviewing a dashboard.
The scientific opportunity is substantial. Personalised analytics can make physiological change visible, while adaptive treatment systems can act on measurements within clearly defined limits. Europe’s next step is to match these capabilities to care pathways with realistic staffing and tested responses. Success will be a useful change in treatment or health, delivered in a way that people can sustain at home.
